Evidence map›Paper›PMID 22214752›Full record

Trial reportThe international journal of neuropsychopharmacology2012

Acute modafinil exposure reduces daytime sleepiness in abstinent methamphetamine-dependent volunteers.

James J Mahoney, Brian J Jackson, Ari D Kalechstein, Richard De La Garza, Lee C Chang, Thomas F Newton

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The international journal of neuropsychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. The use ofFrontiers in cell and developmental biology · 2026
    Review
  3. Modafinil, an atypical CNS stimulant?Advances in pharmacology (San Diego, Calif.) · 2024
    Article
  4. Review
  5. Review
  6. Modafinil potentiates cocaine self-administration by a dopamine-independent mechanism: possible involvement of gap junctions.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Article
  7. Review
  8. Article
  9. Review
  10. Pharmacotherapy for stimulant-related disorders.Current psychiatry reports · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

James J MahoneyBaylor College of Medicine, Menninger Department of Psychiatry and Behavioral Sciences, Houston, TX, USA. james.mahoney@bcm.edu
Brian J Jackson
Ari D Kalechstein
Richard De La Garza
Lee C Chang
Thomas F Newton
Michael E. DeBakey VA Medical Center · US

Funding

ZDV &3TC NEVIRAPINE COMBINATION THERAPY IN HIV 1 INFECTED INFANTS &M01RR000865 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WASHINGTON, ARNOLD E. · 1985 to 2011
$43.4M
UCLA Medication Development Unit for Stimulant AbuseP50DA018185 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHOPTAW, STEVEN J · 2004 to 2009
$5.8M
An ACE Inhibitor as a Treatment for Methamphetamine DependenceR01DA023468 · NIDA · BAYLOR COLLEGE OF MEDICINE · PI NEWTON, THOMAS FREDERICK · 2008 to 2012
$1.9M
Clinical Research Education for Drug Abuse ProfessionalsR25DA014593 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEWTON, THOMAS FREDERICK · 2002 to 2006
$1.3M
Assess of Stress Effects in Methamphetamine DependenceK24DA017754 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEWTON, THOMAS FREDERICK · 2005 to 2010
$727k
Perindopril-Methamphetamine Interaction StudyR21DA017182 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEWTON, THOMAS FREDERICK · 2003 to 2006
$410k
NCRR NIH HHS M01 RR000865NCRR NIH HHS RR-00865NIDA NIH HHS DA 014593NIDA NIH HHS DA 017754NIDA NIH HHS DA 18185NIDA NIH HHS K24 DA017754NIDA NIH HHS P50 DA018185NIDA NIH HHS R01 DA023468NIDA NIH HHS R21 DA017182NIDA NIH HHS R25 DA014593
6 · The paper itself

Abstract

The purpose of this study was to evaluate the effects of acute, oral modafinil (200 mg) exposure on daytime sleepiness in methamphetamine (Meth)-dependent individuals. Eighteen Meth-dependent subjects were enrolled in a 7-d inpatient study and were administered placebo or modafinil on day 6 and the counter-condition on day 7 (randomized) of the protocol. Subjects completed several subjective daily assessments (such as the Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Beck Depression Inventory and visual analogue scale) throughout the protocol as well as objective assessments on days 5-7, when the Multiple Sleep Latency Test was performed. The results of the current study suggest that short-term abstinence from Meth is associated with increased daytime sleepiness and that a single dose of 200 mg modafinil reduces daytime somnolence in this population. In addition, a positive correlation was found between subjective reporting of the likelihood of taking a nap and craving and desire for Meth, as well as the likelihood of using Meth and whether Meth would make the participant feel better. The results of this study should be considered when investigating candidate medications for Meth-dependence, especially in those individuals who attribute their Meth use to overcoming deficits resulting from sleep abnormalities.

Indexed as

MethamphetamineAdultAmphetamine-Related DisordersBenzhydryl CompoundsCentral Nervous System StimulantsCognitionDemographyDiagnostic and Statistical Manual of Mental DisordersDouble-Blind MethodFemaleHumansMaleModafinilNeuropsychological TestsPolysomnographyPsychiatric Status Rating ScalesBenzhydryl CompoundsCentral Nervous System StimulantsMethamphetamineModafinil

Identifiers

PMID22214752
PMCPMC3411896
OpenAlexW2137716010

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.